| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCC1; COCA1; HNPCC; LCFS2; hMSH2; HNPCC1; MMRCS2 |
| Entrez GeneID | 4436 |
| clone | 1H8C1 |
| WB Predicted band size | 104.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MSH2 (AA: 2-151) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MSH2抗体的代表性文献概览：
---
1. **文献名称**: "Immunohistochemistry screening of MSH2 mutations in Lynch syndrome using novel antibody panels"
**作者**: Gatalica Z, et al.
**摘要**: 研究验证了MSH2抗体在免疫组化(IHC)中检测错配修复缺陷的敏感性和特异性，发现其可作为Lynch综合征和散发性结直肠癌的筛查工具，与基因测序结果高度一致。
---
2. **文献名称**: "Antibody-based detection of MSH2 protein loss in endometrial and colorectal cancers"
**作者**: Peltomäki P, et al.
**摘要**: 通过对比多种商用MSH2抗体的性能，发现克隆FE11和25D12在子宫内膜癌和结直肠癌中检测蛋白缺失的可靠性最高，支持其在临床病理诊断中的应用。
---
3. **文献名称**: "MSH2 deficiency as a prognostic marker in microsatellite-unstable tumors"
**作者**: Shia J, et al.
**摘要**: 分析MSH2抗体IHC结果与肿瘤微卫星不稳定(MSI)状态的关联，证明MSH2蛋白缺失与特定亚型癌症的预后不良相关，并提示其可能指导免疫治疗选择。
---
以上文献聚焦于MSH2抗体的临床应用验证、技术优化及预后研究，为相关肿瘤诊断和机制探索提供参考。如需具体DOI或发表年份可进一步补充。
The MSH2 antibody is a crucial tool in molecular pathology and cancer research, primarily used to detect the MSH2 protein encoded by the MutS homolog 2 (MSH2) gene. MSH2 is a key component of the DNA mismatch repair (MMR) system, which corrects replication errors to maintain genomic stability. It forms heterodimers (e.g., with MSH6 or MSH3) to recognize mismatched nucleotides, initiating repair processes. Defects in MSH2 disrupt MMR function, leading to microsatellite instability (MSI) and an increased risk of cancers, notably Lynch syndrome-associated malignancies (colorectal, endometrial, gastric).
In diagnostics, MSH2 antibodies are employed in immunohistochemistry (IHC) to assess protein expression in tumor tissues. Loss of MSH2 expression suggests MMR deficiency, aiding in Lynch syndrome screening or identifying sporadic MSI-high tumors. This has prognostic and therapeutic implications, as MSI-high tumors may respond differently to therapies like immune checkpoint inhibitors.
Commercial MSH2 antibodies are typically monoclonal, validated for specificity and sensitivity. Interpretation requires correlation with clinical data and other MMR protein assays (MLH1. PMS2. MSH6) to confirm hereditary or acquired defects. Research applications include studying MMR mechanisms, carcinogenesis, and targeted therapies. Standardized protocols and controls are essential to ensure accuracy, given potential pitfalls like variable staining or antibody cross-reactivity.
×
